Establishment of a HEK293T cell line able to site-specifically integrate and stably express GDNF by rAAV-2 vector
Reprint PDF

Keywords

glial cell line-derived neurotrophic factor
multiplicity of infection
recombinant adeno-associated virus 2
site-specific integration
transduction

How to Cite

1.
Zhang J, Zhang Y, Liu X, Xiang J, Zhang C. Establishment of a HEK293T cell line able to site-specifically integrate and stably express GDNF by rAAV-2 vector. Electron. J. Biotechnol. [Internet]. 2016 Jul. 15 [cited 2024 Sep. 19];22. Available from: https://preprints.pucv.cl/index.php/ejbiotechnology/article/view/2016.05.001

Abstract

Background: Using recombinant adeno-associated virus 2 (rAAV-2), we attempted to establish a HEK293T cell line that is able to site-specifically integrate and stably express glial cell line-derived neurotrophic factor (GDNF).

Results: Recombinant vector with enhanced green fluorescent protein (EGFP) and GDNF (pTR-P5-EGFP-IRES-GDNF), as well as that carrying Rep genes and SV40 promoters (pSVAV2) were constructed and packed. HEK293T cells were co-infected with rAAV-2/EGFP-GDNF and rAAV-2/SVAV2 virus separately at 1 × 104, 1 × 105, and 1 × 106 of multiplicity of infection (MOI). The efficiency of transduction was detected using flow cytometry. Additionally, the infected HEK293T cells were separately validated by touchdown polymerase chain reaction (PCR) and Western-blot. After 72 h of transduction, the rate of EGFP positive cell was 22%, 45% and 49% at the MOIs of 1 × 104, 1 × 105 and 1 × 106, respectively. On the 3rd, 6th and 9th day of cell passage, there was no significant difference in the cell viability and proliferation rate between transduction and control groups. Importantly, touchdown PCR showed that there was a specific PCR amplified product band in the lane of infected cells. Furthermore, GDNF expression was detected in the infected cells after 15 and 180 d of cultivation.

Conclusions: A HEK293T cell line able to site-specifically integrate and stably express GDNF was established.

Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.